De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Supernus Pharmaceuticals Beheer
Beheer criteriumcontroles 2/4
De CEO Supernus Pharmaceuticals' is Jack Khattar, benoemd in Jan2005, heeft een ambtstermijn van 19.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 13.28M, bestaande uit 7.3% salaris en 92.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.54% van de aandelen van het bedrijf, ter waarde $ 60.76M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 9.5 jaar en 14.8 jaar.
Belangrijke informatie
Jack Khattar
Algemeen directeur
US$13.3m
Totale compensatie
| Percentage CEO-salaris | 7.3% |
| Dienstverband CEO | 19.8yrs |
| Eigendom CEO | 3.5% |
| Management gemiddelde ambtstermijn | 9.5yrs |
| Gemiddelde ambtstermijn bestuur | 14.8yrs |
Recente managementupdates
Recent updates
Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives
Sep 12Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings
Aug 19
Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout
Jul 02Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price
Apr 24Supernus Pharmaceuticals: Moving Through An 'Inflection Year'
Mar 04We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt
May 10Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?
Feb 03These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well
Oct 19Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment
Oct 10Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio
Aug 19Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear
Aug 16Supernus: A Work In Progress
Jul 29Supernus: New Beginnings
Mar 28Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts
Dec 02Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?
Nov 30Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?
Oct 19Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$5m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$13m | US$963k | US$1m |
| Sep 30 2023 | n/a | n/a | US$26m |
| Jun 30 2023 | n/a | n/a | US$43m |
| Mar 31 2023 | n/a | n/a | US$52m |
| Dec 31 2022 | US$10m | US$914k | US$61m |
| Sep 30 2022 | n/a | n/a | US$38m |
| Jun 30 2022 | n/a | n/a | US$57m |
| Mar 31 2022 | n/a | n/a | US$73m |
| Dec 31 2021 | US$8m | US$870k | US$53m |
| Sep 30 2021 | n/a | n/a | US$82m |
| Jun 30 2021 | n/a | n/a | US$100m |
| Mar 31 2021 | n/a | n/a | US$111m |
| Dec 31 2020 | US$7m | US$836k | US$127m |
| Sep 30 2020 | n/a | n/a | US$129m |
| Jun 30 2020 | n/a | n/a | US$118m |
| Mar 31 2020 | n/a | n/a | US$116m |
| Dec 31 2019 | US$8m | US$812k | US$113m |
| Sep 30 2019 | n/a | n/a | US$106m |
| Jun 30 2019 | n/a | n/a | US$105m |
| Mar 31 2019 | n/a | n/a | US$103m |
| Dec 31 2018 | US$7m | US$724k | US$111m |
| Sep 30 2018 | n/a | n/a | US$99m |
| Jun 30 2018 | n/a | n/a | US$87m |
| Mar 31 2018 | n/a | n/a | US$73m |
| Dec 31 2017 | US$6m | US$614k | US$57m |
Compensatie versus markt: De totale vergoeding ($USD 13.28M ) Jack } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).
Compensatie versus inkomsten: De beloning van Jack is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.
CEO
Jack Khattar (63 yo)
19.8yrs
Tenure
US$13,278,093
Compensatie
Mr. Jack A. Khattar, M.B.A., founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as Chief Executive Officer, President, Secretary and Director since 2005. He...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 19.8yrs | US$13.28m | 3.54% $ 62.5m | |
| Senior VP & CFO | 3.2yrs | US$2.38m | 0.013% $ 230.6k | |
| Chief Scientific Officer & Senior VP of Intellectual Property | 12.6yrs | US$1.47m | 0.018% $ 310.2k | |
| Senior Vice President of Quality | 4.8yrs | US$1.79m | 0.014% $ 249.5k | |
| Senior VP of Research & Development and Chief Medical Officer | 4.7yrs | US$1.59m | 0.0084% $ 148.8k | |
| Compliance Officer | 12.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Marketing | 9.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Sales | 9.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Corporate Development | 9.3yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Supply Chain | 3.4yrs | geen gegevens | geen gegevens |
9.5yrs
Gemiddelde duur
63yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van SUPN is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 19.8yrs | US$13.28m | 3.54% $ 62.5m | |
| Independent Chairman of the Board | 19.8yrs | US$407.02k | 0.22% $ 3.9m | |
| Independent Director | 9.6yrs | US$378.52k | 0.024% $ 426.8k | |
| Independent Director | 6.3yrs | US$376.02k | 0.031% $ 551.4k | |
| Independent Director | 14.8yrs | US$385.02k | 0.067% $ 1.2m |
14.8yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SUPN zijn ervaren en ervaren (gemiddelde ambtstermijn van 14.8 jaar).